Abstract:The essential trace element iron is a key component of hemoglobin, playing a role in erythropoiesis and oxygen transport. In addition, iron plays a key role in several enzymatic and metabolic processes. Iron deficiency causes anemia, whereas iron overload causes organ-related diseases such as heart failure, liver cirrhosis, and diabetes mellitus. Therefore, maintaining iron homeostasis is essential for the survival of nearly all living organisms. Iron overload-related cardiomyopathy is a secondary form of heart disease resulting from iron accumulation in the myocardium and is the leading cause of morbidity in hereditary hemochromatosis, thalassemia major, and other conditions associated with secondary iron overload. A growing body of epidemiological and molecular evidence supports the notion that iron overload is pathogenic and that iron chelation therapy can be clinically beneficial in treating many forms of heart disease. However, the precise mechanisms by which iron overload leads to heart disease are poorly understood. In recent years, significant progress has been made toward understanding the regulatory mechanisms that underlie iron overload in many diseases. In particular, ferroptosis, a newly identified iron-dependent form of cell death, has drawn considerable attention. Ferroptosis has morphological, biochemical, and genetic features that are distinct from other forms of cell death such as apoptosis, necrosis, and autophagy, and mounting evidence suggests that ferroptosis participates in the initiation and progression of many diseases and conditions, including tumorigenesis, ischemia/reperfusion injury, kidney failure, and diseases affecting the nervous system and the hematological system. Although the death of terminally differentiated cardiomyocytes is a crucial pathogenic factor in the development of cardiomyopathy, the underlying mechanism remains unknown. Recently, we reported that inhibiting ferroptosis in mice can protect against both chemotherapy-induced cardiomyopathy and ischemia/reperfusion-induced cardiomyopathy. With respect to the underlying mechanism, we found that excess accumulation of free iron in the mitochondria of cardiomyocytes causes membrane lipid peroxidation, providing new insights into the pathogenic mechanisms that underlie iron overload-associated cardiomyopathy. In this review, we briefly introduce the molecular mechanisms that regulate cardiac iron homeostasis. In addition, we provide an overview of studies regarding the role that iron overload-associated cardiomyopathy and ferroptosis play in the pathogenesis and progression of heart disease. Finally, we discuss the role of targeting ferroptosis as a promising new therapeutic strategy for myocardial chemotherapeutic and ischemia/reperfusion injury.

[Iron and stable ischemic heart disease - lessons from heart failure]

Identification of three mechanistic pathways for iron-deficient heart failure

Iron deficiency in myocardial ischaemia: molecular mechanisms and therapeutic perspectives

Iron and cardiovascular health: A review

Iron homeostasis in the heart: Molecular mechanisms and pharmacological implications

Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity

Role of Iron Overload and Ferroptosis in Heart Disease

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction

Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver

Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology

Pre-emptive iron supplementation prevents myocardial iron deficiency and attenuates adverse remodelling after myocardial infarction

Iron in kidney and heart failure: from theory to practice

Iron deficiency and supplementation in heart failure

Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron‐deficient heart failure

Anemia and Iron Deficiency in Heart Failure — Clinical Update

The Molecular Mechanisms of Iron Metabolism and Its Role in Cardiac Dysfunction and Cardioprotection

Role of Iron Deficiency in Heart Failure—Clinical and Treatment Approach: An Overview

Iron deficiency and cardiovascular disease

Systemic iron deficiency does not affect the cardiac iron content and progression of heart failure

Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets

[Iron deficiency in cardiovascular disease]